InhibOx, a leading developer of novel and effective computational methods for drug discovery, has joined forces with MolPort, an innovator in rare chemical trading. MolPort focuses on developing rare chemical trading platform and builds database of commercially available compounds. Now we provide this database and its updates to computational chemists at InhibOx where they incorporate it into the virtual screening procedures. Once they identify suitable lead candidates, MolPort offers to efficiently source these compounds and deliver to the client for testing.
(PRWEB) December 4, 2009 -- InhibOx Ltd (Oxford, UK) and MolPort Ltd (Riga, Latvia) announce a strategic partnership to deliver integration in library design and compound provision.
InhibOx, a leader in drug lead identification and library design software and service, uses breakthrough proprietary technology to offer an on-demand virtual screening capability which has demonstrated dramatically improved results over traditional high throughput screening methods. The company has partnered with MolPort, the innovative compound provision consolidator/specialist.
Together, the two companies are able to provide a new, unique service which delivers novel lead candidates in the form of a rich data set and high quality compound samples. Frequently virtual screening identifies compound sets for testing which must be sourced from multiple suppliers, imposing a logistical problem, especially for smaller companies. This integrated service removes these bottlenecks, allowing much improved access to commercially available molecules.
Dr. Paul Finn, CEO of InhibOx, sees this as an important breakthrough in outsourced screening services. “InhibOx goes further than anyone else in value-added virtual screening, and the results bear this out. By adding library sample provision to the service, through MolPort’s hig
Copyright©2009 Vocus, Inc.
All rights reserved